Cannabis in Neuropsychopharmacology (STUDY 2019)

  • Cannabis in Neuropsychopharmacology (STUDY 2019)

Narcotic effects on systems in the human body can lead to serious mental disorders including psychosis or schizophrenia.


Extract from the study

The major psychoactive substance in cannabis is Δ9-tetrahydrocannabinol (THC), which is a partial agonist of the endocannabinoid CB1 receptor. Cannabis and THC produce a wide range of effects on neurocognitive and pharmacological systems.

These effects affect powerful, emotional and memory processes that are driven through direct interactions with the endocannabinoid system and indirect interactions with glutamatergic, GABAergic and dopaminergic systems.

Cannabidiol, an infamous cannabinoid found in some types of cannabis, can counteract these effects.

Very frequent use of cannabis, especially during adolescence, is associated with adverse effects on these systems. This increases the risk of mental illnesses such as addiction or psychosis.

In this study, we focused on providing a general review of research into the chronic neuropsychopharmacology of cannabis. We used available research on neuroimaging in humans.

We explain the effects of drug use during development and its consequences to understand the psychosis and other disorders associated with cannabis use. A better understanding of the whole mechanism that produces cannabis effects could provide new goals for the entire treatment.

Key words: addiction, cannabis, cognition, development, neuroimaging, psychosis


Authors: Michael A.P. Bloomfield, Chandni Hindoch, Sebastian F. Green, Matthew B. Wall, Rachel Lees, Katherine Petrilli, Harry Costello, M. Olabisi Ogunbiyi, Matthijs G. Bossong, Tom P. Freeman
You can read more of this study at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416743/. The whole study is in English.

Photo source: pixabay.com (author: geralt)